
Orbis Biosciences Inc Profile last edited on: 2/14/2019
CAGE: 57ZQ2
UEI: D3GMZSP2W9U7
Business Identifier: Controlled-release delivery systems for pharmaceutical, consumer product, chemical, and food and beverage industries Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Multiple
Congr. District: 03
County: Wyandotte
Congr. District: 03
County: Wyandotte
Public Profile
Orbis Bioscience provides novel controlled-release delivery systems to companies looking to reinvent their products through unprecedented control of particles. This control involves the physical levers of particlesparticle uniformity, precise shell thickness, exact porosity to achieve precise release rates and better quality through uniform, reproducible particles. Using Precision Particle Fabrication (PPF) technology, Orbis can improve many products to provide desired delivery rates, including sustained, constant, and pulsatile release profiles. Orbis Biosciences currently supports research for multiple human and animal pharmaceutical, food and flavor, and consumer product company clients interested in developing new controlled-release delivery systems to improve their products. By partnering with companies, Orbis provides R&D services to help clients integrate PPF technology into their products
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
15-19Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2017 | 1 | NIH | $224,963 | |
Project Title: Precision Microspheres for Transtympanic Delivery of Ganciclovir for CMV Infection | ||||
2016 | 2 | NIH | $1,785,897 | |
Project Title: Precision Particle Fabrication-Enabled Betamethasone-Loaded Microspheres for Tran | ||||
2015 | 2 | NIH | $2,398,491 | |
Project Title: Expanding Precision Particle Fabrication Technology for the Widespread Control Of | ||||
2015 | 2 | NIH | $1,552,106 | |
Project Title: Engineering Microparticles for Taste-Masking and Controlled Release of Pediatric | ||||
2014 | 1 | USDA | $99,069 | |
Project Title: Single-injection, self-contained booster vaccine |
Key People / Management
Maria Stecklein Flynn -- President & CEO
Cory Berkland -- Founder and Chief Scientific Officer
Nathan H Dormer
David W Dumbauld
Bo Fishback -- former President: Founder & Advisor
Terry J Shelton -- Special Advisor for Business Development
Milind Singh -- Director of Technology
Cory Berkland -- Founder and Chief Scientific Officer
Nathan H Dormer
David W Dumbauld
Bo Fishback -- former President: Founder & Advisor
Terry J Shelton -- Special Advisor for Business Development
Milind Singh -- Director of Technology